2019年3月22日 ASLAN Pharmaceuticals reports Fourth Quarter and Full Year 2018 Financial Results and provides Corporate Update
2019年3月11日 ASLAN Pharmaceuticals signs new agreement with BioGenetics for commercialisation of ASLAN003 in South Korea
2019年2月27日 ASLAN Pharmaceuticals to partner with Biogenetics on commercialisation of varlitinib in South Korea
2019年1月30日 ASLAN Pharmaceuticals announces strategic prioritisation of clinical development programs and corporate restructuring
2019年1月23日 ASLAN announces publication of new pre-clinical data demonstrating the activity of varlitinib in TNBC cell lines
2019年1月15日 ASLAN Pharmaceuticals to present positive varlitinib data in first-line biliary tract cancer in combination with chemotherapy at ASCO GI
2019年1月14日 ASLAN Pharmaceuticals announces study results from phase 2 study of varlitinib in first-line gastric cancer
2019年1月4日 ASLAN Pharmaceuticals announces IND submission for ASLAN003 to U.S. FDA and conclusion of 30-day review period
2019年1月2日 ASLAN Pharmaceuticals completes enrolment for global pivotal TreeTopp study ahead of schedule
2018年12月3日 New data on ASLAN003 presented at ASH Annual Meeting shows first signs of clinical activity of a DHODH Inhibitor in Acute Myeloid Leukaemia
2018年11月27日 ASLAN Pharmaceuticals announces acceptance of abstracts on new varlitinib data in BTC at ASCO Gastrointestinal Cancers Symposium
2018年11月8日 ASLAN Pharmaceuticals reports third quarter 2018 financial results and provides corporate update